- $7.31bn
- $7.39bn
- $3.90bn
- 86
- 89
- 84
- 98
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,072 | 1,083 | 1,580 | 3,647 | 3,897 |
Cost of Revenue | |||||
Gross Profit | 1,236 | 642 | 919 | 2,302 | 2,216 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1,913 | 5,086 | 770 | 2,063 | 2,623 |
Operating Profit | 159 | -4,002 | 809 | 1,584 | 1,273 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -123 | -4,037 | 188 | 1,384 | 1,339 |
Provision for Income Taxes | |||||
Net Income After Taxes | -90.6 | -3,771 | 189 | 1,430 | 1,024 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -128 | -3,690 | 320 | 1,856 | 1,024 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -128 | -3,690 | 320 | 1,856 | 1,020 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.344 | -51.9 | 2.14 | 44.3 | 23.6 |
Dividends per Share | |||||
Special Dividends per Share |